During fasting, gastrointestinal motility is characterized by cyclical motor contractions.
Introduction
Ghrelin was first identified in rat stomach as an endogenous ligand for growth hormone secretagogue receptors (GHS-R). (17) Ghrelin molecules exist in the stomach and hypothalamus in 2 major endogenous forms: one form acylated at serine 3 (ghrelin) and in a desacylated form (des-acyl ghrelin). (13) Ghrelin stimulates GH secretion by binding to type 1a GHS-R, and acylation is essential for this binding. Des-acyl ghrelin is unable to initiate GH release. Hence, acylated ghrelin has been known as the active form and des-acyl ghrelin as the inactive form of the peptide. (7, 13, 18) Ghrelin is involved in various functions, including GH release, control of food intake and energy balance,(2, 40) glucose metabolism and insulin release, (6, 31) and cardiovascular actions. (4, 23) Ghrelin has also been reported to stimulate gastrointestinal (GI) motility in rats and humans. (12, 20, 36) We have previously shown that ghrelin stimulates GH release in a dose-dependent manner. However, it does not stimulate digestive tract motor activity in either the fasted or the fed state in dogs. (25) Moreover, an intravenous (i.v.) injection of high-dose canine ghrelin significantly reduces the motility index (MI) in the gastric body (GB) in the fasted state. (25) In the interdigestive fasting period, the stomach and small intestine, including the duodenum, show cyclically remarkable motor contractions. These contractions have been called interdigestive migrating Ghrelin structurally resembles motilin, and they share an almost 50% similarity in 6 their amino acid sequences. The receptors of both peptides belong to the same family of G protein-coupled receptors and share 53% overall amino acid sequence identity.
On the basis of this structural similarity, these peptides are considered to be members of a new motilin-ghrelin peptide family. (29) A recent study showed that peaks in plasma ghrelin levels were frequently observed 20 to 25 min after peaks in plasma motilin levels in dogs.(43) However, how these 2 peptides influence each other in vivo has not been clarified.
The aim of our study was to investigate the relationship between ghrelin and motilin in conscious dogs.
Materials and methods

Animal preparation
Twenty healthy beagle dogs of both sexes weighing 10 to 12 kg were used. The procedures were approved by the Review Committee on Animal Use of Gunma University, Maebashi, Japan. The dogs were anesthetized with a single i.v. injection of thiopental sodium (Ravonal; Tanabe Pharmaceutical Co. Ltd., Osaka, Japan) at a dose of 20 mg/kg/body weight, and general anesthesia was maintained by intratracheal inhalation of halothane (Fluothane; Takeda Chemical Industries Ltd., Osaka, Japan) and oxygen.
A silastic tube (Silastic 602-205; Dow Corning, Midland, MI, USA) was inserted 7 into the superior vena cava through a branch of the right external jugular vein (jugular cannula) and used for withdrawal of blood samples and administration of injections.
The jugular cannula was exteriorized through a skin incision on the neck and its outer end was fixed to the adjacent skin with silk sutures. After the abdominal cavity was opened, force transducers were implanted onto the serosal surfaces of the gastric body Inc., Funabashi, Japan).
Monitoring of GI contractions
The wires from the transducer were connected to a telemeter, and the data were transmitted to the recording system (Eight Star system, Star Medical, Tokyo, Japan).
The recorded signals were used to determine the MI. The MI was the integrated area 8 between the baseline (zero level) and contractile wave expressed as motor units measured by the Eight Star system. In addition, the data were used to identify each phase of the contractile activity.
Measurement of active ghrelin and plasma motilin
Whole blood samples were transferred into chilled tubes containing ethylenediaminetetraacetic acid-2Na and 500 U apoprotin, and centrifuged at 4°C at 3000 × g. Two plasma samples were immediately collected; one was used for ghrelin measurement, and the other was used for motilin measurement. For measuring the acylated ghrelin by ELISA, 0.1 mL of 1-N hydrochloric acid per mL of plasma sample was added to the sample. All plasma samples were stored at -80°C until hormone analyses were performed.
The plasma acylated ghrelin concentration was measured using an ELISA kit (Mitsubishi Kagaku Iatron, Inc., Tokyo, Japan). This kit employs a polyclonal antibody against N-terminal fragments containing n-octanoylated serine at position 3.
These assay kits were designed for rats, mice, and humans. However, according to a recent study, canine ghrelin was able to be measured accurately with this kit. (41) The plasma concentration of motilin was measured by radioimmunoassay. Each tube containing 100 μL of a standard or unknown sample, 100 μL of rabbit anticanine motilin serum (RC91T), 200 μL of assay buffer for the unknown sample, or 100 μL of assay buffer and 100 μL of hormone-free serum was prepared by charcoal extraction.
The RC91T antiserum was diluted to a final concentration of 1:150 000. After incubation of the tubes for 24 h at 4°C, 10 μL of 125 I-(try 23 ) canine motilin (10 000 counts/min), which was prepared as previously described previously,(21, 32) was added to the tubes, followed by further incubation for 24 h at 4°C. The second antiserum (200 μL) was added to the tubes and incubated at room temperature for 2 h. Bound and free 125 I-motilin were separated by centrifugation at 3000 × g for 15 min. The supernatant was discarded, and the precipitate was counted in a Packard COBLA gamma counter (Downers Grove, IL).
Plasma levels of ghrelin and motilin during the interdigestive state (Examination 1)
Nine dogs were used in Examination 1. Experiments were initiated after confirming that gastric phase III contractions were occurring regularly; it typically took approximately 2 weeks after the procedure for this activity to be restored. After the first or second phase III contractions of the day were confirmed to have occurred, the IMC cycle was recorded at least 2 times in each dog, and blood samples were collected at 15 min intervals. Results of ghrelin and motilin concentrations were averaged and assigned to each phase and compared. Phase I was divided at its midpoint into early 10 phase I and late phase I (Fig. 1 ). In addition, ghrelin and motilin levels were compared at 30 min preceding and 30 min following the end of phase III on GA, and quantitative analysis was performed, as previously described.(28)
Effect of ghrelin on motilin release (Examination 2)
Six dogs were used in Examination 2. Saline or canine ghrelin (10 μg/kg) was administered i.v. as a slow, single-bolus injection during phase II or III contractions.
The subsequent GI motility was recorded for at least 2 h. After randomly receiving ghrelin or saline, each animal was examined on 3 different days. The MI was calculated for the 30 min period after injection. Blood samples were withdrawn from the jugular catheter at -15, 0, 15, 30, 45, 60, 75, 90, 105, and 120 min after the injection, and the ghrelin and motilin plasma concentrations were measured.
Effect of ghrelin on IMC (Examination 3)
Four dogs were used in Examination 3 to observe that ghrelin inhibited phase III. 
Effect of motilin on ghrelin release (Examination 4)
Five dogs were use in Examination 4. To clarify whether motilin regulates ghrelin release in dogs, the reaction of the plasma ghrelin level was evaluated when motilin was administered during phase I. Blood samples were withdrawn from the jugular catheter at -15, 0, 15, 30, 45, 60, 75, 90, 105, and 120 min after the injection of motilin, and ghrelin and motilin plasma concentrations were measured.
Analysis of the MI
GI motility was quantified by calculating the MI that was equivalent to the area under the curve. The MI was calculated using a computer-assisted system (Eight Star system, Version 6.0, Star Medical, Tokyo, Japan). The levels of fasted GI motility were analyzed for 30 min following injection of either saline or canine ghrelin. MI analysis was conducted blind to the saline and ghrelin doses. The MI of canine ghrelin was 12 compared with that of the saline level. The mean of three studies for each dog was calculated, and all data were expressed as means ± SE. The data were subjected to detailed statistical using the ANOVA followed by Fisher's protected least significant difference method. Differences at P-values of <0.05 were considered to be significant.
The statistical calculations were carried out using JMP 5.0 software (SAS Institute, Japan).
Materials
Canine ghrelin [GSS (n-octanoyl) FLSPEHQKLQQRKESKKPPAKLQPR] was synthesized at Shimadzu Co. (Kyoto, Japan). Canine motilin was purchased from ScyTek Laboratories (Logan, UT).
Statistical analysis
All results were expressed as mean values (SEM) for each time point and for each treatment. The data were subjected to further statistical analysis (ANOVA). Time dependent changes in plasma hormone levels were compared by two way ANOVA analysis with repeated measurements on two factors and univariate testing of significance for planned comparisons. The paired data were compared using Student's t-test. P-values of <0.05 were considered statistically significant. The statistical calculations were carried out using JMP 5.0 software (SAS Institute, Japan.).
Results
Plasma concentration of ghrelin in the fasted and fed states (Examination 1)
In the fasted state, IMCs were observed cyclically every 100 to 120 min. The peaks of plasma motilin levels were observed at every gastric phase III (18/18). (Fig.2) Basal motilin levels were 1103 ± 55. (Fig.3) . Motilin levels were compared between pre-phase III and post-phase III. Motilin levels of post-phase III were significantly decreased in comparison to pre-phase III (Fig.4a) . In contrast, ghrelin levels of post-phase III were significantly higher than those in pre-phase III (Fig.4b ).
14
Influence of ghrelin administration on motilin levels and IMC (Examination 2)
When saline injections were administered during gastric phase III contractions in the interdigestive state in conscious dogs, the phase III contractions were unchanged.
When canine ghrelin (10 μg/kg) was injected in phase II of IMCs, phase III was inhibited. Administration of canine ghrelin significantly decreased the MI of the GA (data not shown). When canine ghrelin (10 μg/kg) was injected in phase III of the IMCs, phase III was inhibited, and the MIs of the GB and GA were significantly decreased (Figs.5 and 6). Generally, the plasma concentration of motilin gradually increased during phase II, leading to a maximum level in phase III (Fig.7a) . However, administration of canine ghrelin during phase II and III contractions immediately decreased the plasma concentration of motilin (Fig.7b) .
Effect of ghrelin on IMC (Examination 3)
Examination 3 was performed to prove that ghrelin inhibited phase III. During infusion of canine ghrelin (1μg/kg/hr for 2 hours), phase III was not observed in any dog (Fig.8a) . In contrast, when [D-Lys3]-GHRP-6 (total dose of 70 nmol/kg) was preloaded, conventional phase III was observed in the presence of a canine ghrelin infusion (Fig.8b) . In both experiments, ghrelin levels were increased by the infusion 15 of canine ghrelin. In the setting of ghrelin infusion, motilin levels were suppressed by the high concentration of ghrelin. In the presence of an antagonist, however, motilin levels increased regardless of elevated ghrelin levels and permitted the initiation in phase III. In other words, the rise of motilin levels was inhibited by ghrelin and, as a result, phase III was inhibited.
Influence of motilin administration on ghrelin release (Examination 4)
Canine motilin infusion (0.6 μg/kg/h for 20 min) immediately stimulated phase III contractions of the stomach and duodenum. The plasma concentration of motilin increased, and upon finishing the infusion, gradually decreased. The motilin infusion, in contrast, immediately decreased the plasma concentration of ghrelin, the level of which gradually increased again from the middle stage of the infusion (Fig.9 ).
Discussion
In this study, we demonstrated that ghrelin and motilin influenced each other in vivo in conscious dogs. This is the first study demonstrating that ghrelin administration decreases the plasma concentration of motilin and inhibits phase III of IMCs. A recent study has shown that peak plasma ghrelin levels are frequently observed 20 to 25 min after peak plasma motilin levels in the interdigestive state in conscious dogs. Ghrelin 16 peaks are observed in early phase I (43). In this prior study, however, ghrelin peaks followed motilin peaks only 72.2% of the time (13/18) . In the present study ghrelin peaks followed motilin peaks in 83.3% (16/18) of cases. The shorter time intervals for blood sampling may explain this discrepancy. In a recent study, blood was collected at 20-25 min intervals. In the current study, blood samples were collected at 15 min intervals. The peaks of ghrelin may only persist for a short length of time and be missed by longer intervals of blood sampling.
The results of the present study indicate that ghrelin regulates the function and release of motilin, and that motilin might be the regulator of ghrelin. The negative results of canine ghrelin in our previous study suggest that ghrelin does not stimulate fasted GI motility in dogs. In the previous study, however, ghrelin was administered in phase I of IMCs. An i.v. injection of canine ghrelin (10 μL/kg) has been shown to significantly reduce the MI in the GB during phase I contractions. (25) This result may suggest that ghrelin competitively inhibits motilin because ghrelin has a structural resemblance to motilin and the ghrelin receptor exhibits a 50% identity with the motilin receptor.(3) As indicated by Peeters, these results suggest that both peptides may cross-react with their receptors. (26) In the present study, ghrelin decreased plasma motilin levels and inhibited phase III. As shown in Figure 8a and 8b, increase of motilin levels was not observed during ghrelin infusion, and IMCs were suppressed.
After two hours, the release of motilin began again. Conversely, when the ghrelin antagonist was preloaded, motilin release was not inhibited and conventional phase III was observed. These results suggest that ghrelin inhibits the release of motilin.
The present study shows that ghrelin inhibits gastric, but not duodenal, phase III One reason for this may be that the reactivity of ghrelin may be different in humans and dogs. For example, ghrelin acts to stimulate the motilin receptor in humans.
Conversely, ghrelin acts to inhibit the release of motilin in dogs.
In humans, preprandial ghrelin peaks are observed(8), while conversely motilin peaks are observed late phase II and phase III of IMC (19) . Because IMCs are observed in the interdigestive states, preprandial motilin peaks may also occur. Furthermore, motilin peaks might be observed before the peaks of ghrelin. In humans, whether a similar cooperative effect by ghrelin and motilin exists is unclear; however it is plausible that the two peptides are associated.
Our previous study has shown that exogenous motilin stimulates endogenous motilin In conclusion, the results of the present study suggest that gastric phase III and motilin release are terminated by increases in plasma ghrelin. We revealed the presence of cooperative regulation of motilin and ghrelin in the function of gastric IMCs in conscious dogs.
Perspectives and Significance
Understanding the mechanisms of IMCs may provide important insights in developing treatments for a variety of functional gastrointestinal diseases. The present study suggests that IMCs are regulated by interactions between ghrelin and motilin. The IMC is composed of three phases. Fig.1 shows each phase. Phase I is divided into early and late sub-phases at the midpoint. 
